Loading stock data…
EXEL
$43.68-0.78 (-1.75%)
Market ClosedLast close May 1
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Exelixis, Inc. in the Healthcare sector is trading at $43.68. The stock is currently 12% below its 52-week high of $49.62, remaining 4.8% above its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why EXEL maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$43.68
Potential Upside
40.7%
Whystock Fair Value$61.45
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Buy
Mean target$47.53+8.8%
Range$35.00 – $60.00
Fundamentals
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced r...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.83B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
16.76
Beta
Defensive asset. Lower volatility than the S&P 500.
0.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
27.87%
Volume
Today's trading volume
3.95M
Recent News
Assessing Exelixis (EXEL) Valuation After Mixed Share Performance And CABOMETYX Growth Narrative
How Exelixis stock has been performing Exelixis (EXEL) has seen mixed share performance recently, with a 1.8% decline over the past day and a 2.8% decline over the past week, while the past 3 months show a 5.6% gain. Over longer periods, the stock reflects a 0.2% year to date return, a 10.3% total return over the past year, a very large 3 year total return of about 12x, and a 5 year total return of 73.9%. See our latest analysis for Exelixis. With the share price at $43.68, recent trading has...
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Dow Jones Stock Merck Skidded 4% — And Boosted A Key Rival
Merck stock skidded Tuesday — while also buoying Exelixis — after the Dow Jones pharma outlet said a triple approach to kidney cancer failed.
Assessing Exelixis (EXEL) Valuation After Recent Short Term Share Price Pressure
Exelixis at a glance: recent returns and business snapshot Exelixis (EXEL) has drawn investor attention after a period where the stock posted a 0.2% move over the past day and a 2.3% decline across the past week. Over the past month, the share price return sits at 6.1%, with about 1% over the past 3 months and 1.8% year to date. The 1 year total return stands at 22.6%, while the 3 year and 5 year total returns are reported at roughly 13x and 8x the starting level respectively. The company,...
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
These companies boast significant upside potential.